Anti-cancer Lead Molecule

Sunil Sagar (Inventor), Mandeep Kaur (Inventor), Luke E. Esau (Inventor)

Research output: Patent


Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative `A` (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative `A` was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative `A` could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative `A` highlights its possible role as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic drugs
Original languageEnglish (US)
Patent numberUS9890106B2
StatePublished - Apr 17 2014

Bibliographical note

KAUST Repository Item: Exported on 2019-02-13


Dive into the research topics of 'Anti-cancer Lead Molecule'. Together they form a unique fingerprint.

Cite this